Editing Bromocriptine (section)

==Medical uses==
Bromocriptine is used to treat [[acromegaly]] and conditions associated with [[hyperprolactinemia]] like [[amenorrhea]], infertility, [[hypogonadism]], and prolactin-secreting [[adenomas]]. It is also used to prevent [[ovarian hyperstimulation syndrome]]<ref name=OlderLabel>{{cite web|title=Bromocriptine mesylate tablets -- original uses|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017962s065s068lbl.pdf|publisher=FDA|date=January 2012|url-status=live|archive-url=https://web.archive.org/web/20170228152534/http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017962s065s068lbl.pdf|archive-date=2017-02-28}} For label updates see [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017962 FDA index page for NDA 017962] {{webarchive|url=https://web.archive.org/web/20170629041043/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017962 |date=2017-06-29 }}</ref><ref>{{cite journal | vauthors = Molitch ME | title = Diagnosis and Treatment of Pituitary Adenomas: A Review | journal = JAMA | volume = 317 | issue = 5 | pages = 516–524 | date = February 2017 | pmid = 28170483 | doi = 10.1001/jama.2016.19699 | s2cid = 205077946 }}</ref><ref>{{cite journal|vauthors=Tang H, Mourad SM, Wang A, Zhai SD, Hart RJ|date=14 Apr 2021|title=Dopamine agonists for preventing ovarian hyperstimulation syndrome|journal=The Cochrane Database of Systematic Reviews|volume=2021 |issue=4 |pages=CD008605 |doi=10.1002/14651858.CD008605.pub4 | pmc=8092425 |pmid=33851429}}</ref> and to treat [[Parkinson's disease]].<ref name=OlderLabel/>

Since the late 1980s it has been used, off-label, to reduce the symptoms of [[cocaine]] withdrawal but the evidence for this use is poor.<ref>{{cite journal | vauthors = Minozzi S, Amato L, Pani PP, Solimini R, Vecchi S, De Crescenzo F, Zuccaro P, Davoli M | title = Dopamine agonists for the treatment of cocaine dependence | journal = The Cochrane Database of Systematic Reviews | issue = 5 | pages = CD003352 | date = May 2015 | volume = 2015 | pmid = 26014366 | pmc = 6999795 | doi = 10.1002/14651858.CD003352.pub4 }}</ref> Bromocriptine has been successfully used in cases of galactorrhea precipitated by dopamine antagonists like [[risperidone]].

A quick-release formulation of bromocriptine, Cycloset, is also used to treat [[type 2 diabetes]].<ref name=DiabetesLabel>{{cite web|title=Bromocriptine mesylate tablet label|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020866s006s007lbl.pdf|publisher=FDA|date=February 2017|url-status=live|archive-url=https://web.archive.org/web/20180513230418/https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020866s006s007lbl.pdf|archive-date=2018-05-13}}. For label updates see [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020866 FDA index page for NDA 020866] {{webarchive|url=https://web.archive.org/web/20170628072832/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020866 |date=2017-06-28 }}</ref><ref>{{cite journal | vauthors = Garber AJ, Blonde L, Bloomgarden ZT, Handelsman Y, Dagogo-Jack S | title = The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations | journal = Endocrine Practice | volume = 19 | issue = 1 | pages = 100–6 | date = 2013 | pmid = 23337160 | doi = 10.4158/EP12325.OR }}</ref><ref>{{cite journal | vauthors = Liang W, Gao L, Li N, Wang B, Wang L, Wang Y, Yang H, You L, Hou J, Chen S, Zhu H, Jiang Y, Pan H | title = Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis | journal = Hormone and Metabolic Research | volume = 47 | issue = 11 | pages = 805–12 | date = October 2015 | pmid = 26332757 | doi = 10.1055/s-0035-1559684 | s2cid = 423132 }}</ref> When administered within 2 hours of awakening, it increases hypothalamic dopamine level.  That results to a significant weight loss as well as decreases in blood glucose levels, hepatic glucose production, and insulin resistance.<ref name=":0">{{cite journal | vauthors = Birhan MT, Ayele TM, Abebe FW, Dgnew FN | title = Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review | journal = Diabetology & Metabolic Syndrome | volume = 15 | issue = 1 | pages = 151 | date = July 2023 | pmid = 37415177 | pmc = 10324265 | doi = 10.1186/s13098-023-01073-2 | doi-access = free }}</ref> It therefore acts as an adjunct to diet and exercise to improve glycemic control and cardiovascular risk.<ref name=":0" /><ref>{{cite journal | vauthors = Defronzo RA | title = Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes | journal = Diabetes Care | volume = 34 | issue = 4 | pages = 789–94 | date = April 2011 | pmid = 21447659 | pmc = 3064029 | doi = 10.2337/dc11-0064 }}</ref>